Bergeron H - Search Results

1

Inconsistencies among European Union pharmaceutical regulator safety communications: a cross-country comparison.

Zeitoun JD, Lefèvre JH, Downing N, Bergeron H, Ross JS. Zeitoun JD, et al. Among authors: bergeron h. PLoS One. 2014 Oct 21;9(10):e109100. doi: 10.1371/journal.pone.0109100. eCollection 2014. PLoS One. 2014. PMID: 25333986 Free PMC article.

2

Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.

Zeitoun JD, Lefèvre JH, Downing NS, Bergeron H, Ross JS. Zeitoun JD, et al. Among authors: bergeron h. Br J Clin Pharmacol. 2015 Oct;80(4):716-26. doi: 10.1111/bcp.12643. Epub 2015 May 28. Br J Clin Pharmacol. 2015. PMID: 25808713 Free PMC article.

3

Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.

Zeitoun JD, Lefèvre JH, Downing NS, Bergeron H, Ross JS. Zeitoun JD, et al. Among authors: bergeron h. Pharmacoepidemiol Drug Saf. 2016 Jun;25(6):687-94. doi: 10.1002/pds.3910. Epub 2015 Nov 11. Pharmacoepidemiol Drug Saf. 2016. PMID: 26554874

4

Crisis and Change: The Making of a French FDA.

Nathanson CA, Bergeron H. Nathanson CA, et al. Among authors: bergeron h. Milbank Q. 2017 Sep;95(3):634-675. doi: 10.1111/1468-0009.12281. Milbank Q. 2017. PMID: 28895229 Free PMC article.

5

Construction of a policy arena: the case of public health in France.

Bergeron H, Nathanson CA. Bergeron H, et al. J Health Polit Policy Law. 2012 Feb;37(1):5-36. doi: 10.1215/03616878-1496002. Epub 2011 Oct 14. J Health Polit Policy Law. 2012. PMID: 22003098

6

What lessons from France's experience could be applied in the United States in response to the addiction and overdose crisis?

Bergeron H, Colson R. Bergeron H, et al. Addiction. 2022 May;117(5):1191-1192. doi: 10.1111/add.15826. Addiction. 2022. PMID: 35373487 No abstract available.

7

[Qualifying policy: taking the example of the alcohol problem].

Bergeron H. Bergeron H. Sante Publique. 2008 Jul-Aug;20(4):341-52. doi: 10.3917/spub.084.0341. Sante Publique. 2008. PMID: 19014085 French. No abstract available.

8

Better data, better policy and better lives: a call for improved drug monitoring and concerted responses.

Comiskey C, Bretteville-Jensen AL, Bergeron H, Bühringer G, Dargan P, Davoli M, Faggiano F, Fischer G, Rodríguez de Fonseca F, Garretsen H, Hickman M, Korf DJ, Krajewski K, Paoli L, Spanagel R. Comiskey C, et al. Among authors: bergeron h. Addiction. 2020 Feb;115(2):199-200. doi: 10.1111/add.14763. Epub 2019 Aug 30. Addiction. 2020. PMID: 31353676 Free article. No abstract available.

9

What drug policies cost: does Europe know how much it is spending to face the drugs phenomenon?

Ballotta D, Bergeron H. Ballotta D, et al. Among authors: bergeron h. Addiction. 2006 Mar;101(3):339-40. doi: 10.1111/j.1360-0443.2005.01364.x. Addiction. 2006. PMID: 16499506 No abstract available.

10

[Health democracy tested].

Bergeron H. Bergeron H. Rev Prat. 2022 Mar;72(3):256-260. Rev Prat. 2022. PMID: 35638945 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

103 results

Search Page